Rezolute is trading 10.84% up now at $4.50 in pre-market after its September 9, 2026 update said the FDA’s review of additional Phase 3 sunRIZE data remains ongoing.

  • The trial missed its primary endpoint and key secondary endpoint, while Rezolute highlighted favorable CGM-based results and potential evidence of glycemic benefit.
  • Broader markets are lower, making the company-specific catalyst more notable.